AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.
AiCuris scientist Dr. Lischka will present detailed mechanism of action evaluations performed with AIC246 during session 15 on "Interventions, Treatment and Prevention" scheduled on Wednesday, July 28, 2010 from 14.30 to 15:45 hrs, Kingsbury Hall Auditorium on the University of Utah campus. The data show that AIC246 specifically targets the processing of the viral DNA and inhibits the formation and release of infectious virus particles.
"Our results clearly indicate that AIC246 is distinct from the marketed polymerase inhibitors against HCMV and has the potential to be of great benefit for patients in need of an anti-HCMV therapy" said Dr. Zimmermann, Chief Scientific Officer of AiCuris. "We have already seen that this unique mechanism of action translates into resistance breaking properties and good tolerability in the clinic. We are excited to develop this novel and highly specific drug as we see a high medical need for an improved therapy and prophylaxis of HCMV infections" comments AiCuris' CEO Prof. Helga Rübsamen-Schaeff.
Scientists uncover two Crohn’s disease subtypes using lab-grown intestines, offering hope for personalized therapies